RE:Revive is currently in discussions with Canadian licensed prI know, right, and producer's' is plural. Crazy low valuation for a biotech that offers a unique product that none of its peers offer and a lucrative pipeline of medical research into CBD. Mid forties is a foolish price to sell at considering the enormous strength in the sector but to each their own. News flow for Q1 should be strong.